Complement Inhibition Functional Assay

Creative Biolabs' complement inhibition functional assay service provides pathway-aware and mechanism-focused evaluation of complement inhibitory activity. Our complement inhibition functional assay platforms are suitable for early discovery screening, lead optimization, potency ranking, mechanism-of-action studies, lot-to-lot comparability, species cross-reactivity assessment, translational biomarker selection, and preclinical package development.

Submit Your Request Now

Download our service brochure

Inquiry

Why Complement Inhibition Functional Assays Matter

Complement activation is not a single linear event. It is a dynamic cascade initiated through the classical, lectin, or alternative pathway and amplified through C3 convertase formation. Downstream events include C3 cleavage, C3b deposition, C5 convertase assembly, C5a generation, terminal pathway activation, and C5b-9 membrane attack complex formation. Because each pathway has different triggers, molecular players, amplification loops, and regulatory checkpoints, functional inhibition must be evaluated in a pathway-resolved manner.

A robust complement inhibition functional assay can answer key questions:

Does your candidate inhibit the classical pathway triggered by antibody-antigen immune complexes?
Does it block lectin pathway activation driven by mannose-binding lectin, ficolins, or MASP-mediated cleavage events?
Does it suppress alternative pathway amplification under Mg-EGTA conditions?
Does it prevent C3b deposition, C3 convertase formation, or downstream opsonization?
Does it block C5 cleavage, C5a release, or terminal C5b-9 assembly?
Does the inhibitor act upstream or downstream of C3 activation?
Does the molecule retain potency in normal human serum, patient serum, plasma, or customized buffer systems?
Does inhibition reduce complement-mediated cell lysis, inflammatory signaling, or biomaterial opsonization?

Creative Biolabs supports these decisions with customized, high-quality functional assay development and execution.

Great Minds Choose Creative Biolabs

Partner with Us

What We Test

Antibody-Based Complement Inhibitors

Creative Biolabs evaluates monoclonal antibodies, bispecific antibodies, Fc-engineered antibodies, antibody fragments, and antibody-like scaffolds designed to inhibit complement targets. We support candidates targeting C1q, C1s, C3, C3b, Factor B, Factor D, properdin, C5, C5a, C5aR, MASP-1, MASP-2, and other pathway-specific components.

Recombinant Protein and Regulator-Based Inhibitors

We design assays for recombinant Factor H derivatives, CR1-based molecules, CD55-related constructs, CD46-related constructs, CD59-related molecules, C1 inhibitor products, fusion proteins, and engineered complement regulatory domains.

Peptides, Aptamers, and Small Molecules

For discovery-stage programs, Creative Biolabs provides scalable functional assays to rank peptide inhibitors, aptamers, macrocycles, small molecules, and fragment-derived inhibitors. We support dose-response profiling, IC50 estimation, pathway selectivity assessment, matrix tolerance testing, and orthogonal confirmation.

Gene Therapy, RNA, and Nucleic Acid Platforms

Creative Biolabs can evaluate whether a complement inhibitory strategy reduces activation triggered by AAV, LNPs, liposomes, exosomes, extracellular vesicles, polymeric carriers, or nucleic acid complexes. Functional endpoints may include reduced C3b/iC3b deposition, lower C5a release, and decreased sC5b-9 formation.

Cell-Based Therapeutics and Engineered Cells

Engineered cells, stem cell-derived products, CAR-T cells, CAR-NK cells, xenogeneic cells, and encapsulated cell products may interact with complement in complex ways. Creative Biolabs offers cell-based complement inhibition assays to evaluate whether candidate inhibitors protect cells from complement-mediated opsonization, lysis, or inflammatory activation.

Discuss Your Needs

Pathway-Resolved Readout Panels

Creative Biolabs recommends selecting readouts based on the expected mechanism of action. A single endpoint may not be sufficient for complex complement programs.

Upstream Inhibition Panel

Designed for inhibitors targeting initiation or early convertase formation.

Amplification Inhibition Panel

Designed for alternative pathway and amplification loop inhibitors.

Terminal Pathway Inhibition Panel

Designed for C5 and MAC inhibitors.

Translational Biomarker Panel

Designed to support preclinical and clinical biomarker strategy.

Assay Formats

Assay Formats	Descriptions
Classical Pathway Inhibition Assay	The classical pathway is typically activated by antibody-antigen immune complexes or antibody-coated target surfaces. Creative Biolabs designs classical pathway inhibition assays using sensitized sheep red blood cells, immune-complex-coated plates, antigen-antibody systems, antibody-coated cells, or customized target surfaces.
Lectin Pathway Inhibition Assay	The lectin pathway is initiated by pattern-recognition molecules such as mannose-binding lectin, ficolins, and collectins, followed by MASP-mediated cleavage of downstream components. Creative Biolabs develops lectin pathway inhibition assays using mannan-coated plates, pathway-selective buffer conditions, serum-based systems, and detection of C4d, C3b, C5a, or terminal complement complex formation.
Alternative Pathway Inhibition Assay	The alternative pathway provides a powerful amplification loop and can be activated by susceptible surfaces under selective conditions. Creative Biolabs supports alternative pathway inhibition testing using rabbit red blood cell hemolysis, zymosan particles, LPS-coated surfaces, pathway-selective buffers, C3b-coated plates, and cell- or particle-based models.
Terminal Pathway Inhibition Assay	Terminal pathway activation involves C5 cleavage, C5b generation, and assembly of C5b-6, C5b-7, C5b-8, and C5b-9. Creative Biolabs provides terminal complement inhibition assays to assess inhibitors targeting C5, C5a, C5b, C6, C7, C8, C9, or MAC assembly.
C3b Deposition Inhibition Assay	C3b deposition is a central marker of complement activation and amplification. Creative Biolabs offers plate-based and flow cytometry-based C3b/iC3b deposition inhibition assays to determine whether a candidate reduces opsonization on proteins, immune complexes, cells, nanoparticles, microbes, or biomaterial surfaces.
C5a and Anaphylatoxin Suppression Assay	C5a is a potent inflammatory mediator that drives neutrophil activation, chemotaxis, endothelial activation, and cytokine amplification. Creative Biolabs can assess whether complement inhibitors reduce C5a generation under pathway-specific or disease-relevant activation conditions.
Cell-Based Complement Inhibition Assay	Cell-based assays provide biological context that purified biochemical systems cannot fully capture. We support assays using tumor cells, endothelial cells, red blood cells, platelets, primary cells, engineered cells, bacteria, yeast, extracellular vesicles, viral vectors, or nanoparticles.
Hemolysis Inhibition Assay	Hemolysis inhibition assays remain widely used for evaluating complement pathway activity. Creative Biolabs provides CH50-like classical pathway inhibition assays and AH50-like alternative pathway inhibition assays.

Design Your Assay Formats

Sample Requirements

Sample requirements vary depending on assay format, species, and readout. The following general guidelines can support project planning.

Serum or Plasma

Fresh frozen serum is preferred for most activation assays
Avoid repeated freeze-thaw cycles
EDTA plasma is generally not suitable for activation readouts
Citrate plasma may be used for selected applications with careful interpretation
Provide donor information or disease status when relevant

Cells

Provide viability, passage number, culture condition, and marker information
Suspension cells, adherent cells, primary cells, engineered cells, and target-coated cells can be supported
Ship in validated medium or cryopreserved format as appropriate

Particles, Vectors, and Biomaterials

Provide particle concentration, size, surface chemistry, buffer composition, and storage condition
For nanoparticles or viral vectors, provide particle count, genome titer, or mass concentration when available
For biomaterials, provide dimensions, surface area, coating details, sterilization method, and handling instructions

Controls and Reference Materials

Positive inhibitors, negative controls, isotype controls, vehicle controls, heat-inactivated serum, complement-depleted serum, or pathway-specific controls may be included depending on the assay.
If no reference inhibitor is available, Creative Biolabs can recommend suitable control strategies.

Customization Options

Every complement inhibition program is different. Creative Biolabs provides extensive customization to maximize biological relevance.

Customization	Descriptions
Pathway Customization	Classical pathway-biased conditions Lectin pathway-biased conditions Alternative pathway-selective conditions Terminal pathway-focused readouts Amplification loop-specific designs Combined pathway panels
Readout Customization	Colorimetric ELISA Chemiluminescence Fluorescence Flow cytometry Multiplex immunoassay Hemolysis Cell viability Plate-based deposition Microscopy-compatible detection
Matrix Customization	Normal human serum Patient serum Species-specific serum Complement-depleted serum Reconstituted serum Low-serum systems High-serum challenge conditions Customized buffer systems
Analysis Customization	IC50 calculation Percent inhibition Maximum inhibition Residual activity Dose-response modeling Candidate ranking Lot-to-lot comparison Species cross-reactivity comparison Mechanistic interpretation

Design Your Customization

Case Studies

Case 1

Complement classical pathway test and alternative pathway test

The researchers developed a model system to form purified alternative pathway (AP) C5 convertases on C3b-coated beads and quantify C5 conversion via functional analysis of released C5a. Then, they developed a C3aR cell reporter system that enables functional discrimination between C3 and C5 convertases. Their models enable functional characterization of purified convertase enzymes and provide a platform for the identification and development of specific convertase inhibitors for treatment of complement-mediated disorders.

Functional characterization of inhibition using purified models. (OA Literature) Fig. 1 The effect of inhibitors on classical pathway C3 and C5 conversion.^1,2

References

Zwarthoff, Seline A., et al. "Functional characterization of alternative and classical pathway C3/C5 convertase activity and inhibition using purified models." Frontiers in immunology 9 (2018): 1691. https://doi.org/10.3389/fimmu.2018.01691
Distributed under Open Access license CC BY 4.0, without modification.

What Our Clients Say

"We were comparing several biologic inhibitors with different proposed mechanisms. Creative Biolabs designed a cascade-spanning panel that separated upstream inhibition from terminal pathway blockade. The final report was concise, well-structured, and immediately useful for internal decision-making."

— Director of Translational Biology, Biopharmaceutical Company

"We needed more than a standard CH50 or AH50 readout. Creative Biolabs combined hemolysis, C3b deposition, C5a, and sC5b-9 analysis to build a functional inhibition story around our candidate. The results clarified where our molecule acted in the complement cascade."

— Principal Investigator, Academic Immunology Laboratory

"Creative Biolabs supported our nanoparticle complement inhibition study with a customized particle-based assay. Their team helped us compare surface modifications and soluble inhibitors, which gave us a clearer path for formulation optimization."

— Head of Formulation Research, Nanomedicine Company

"Our inhibitor showed different activity across pathway-specific assay formats. Creative Biolabs helped us interpret the difference rather than treating it as conflicting data. Their explanation of classical, alternative, and terminal pathway readouts was very helpful."

— Scientist, Immunology Discovery Group

Frequently Asked Questions

How do you choose the right complement inhibition functional assay for my candidate?

The assay format is selected according to the candidate's target, proposed mechanism of action, development stage, species requirement, and intended decision point. For example, a C1s or C1q inhibitor is typically evaluated under classical pathway-biased conditions, while a Factor B or Factor D inhibitor requires alternative pathway-selective conditions. A C5 inhibitor may require terminal pathway endpoints such as C5a, sC5b-9, and hemolysis inhibition.

What sample types can be evaluated?

We can evaluate antibodies, recombinant proteins, peptides, aptamers, small molecules, fusion proteins, complement regulators, nucleic acid delivery systems, viral vectors, nanoparticles, biomaterials, engineered cells, primary cells, and other customized test articles. Normal human serum, donor-specific serum, disease-state serum, species-specific serum, depleted serum, and reconstituted serum systems can also be incorporated.

Can you distinguish upstream inhibition from terminal pathway inhibition?

Yes. This is one of the major advantages of a multi-readout functional assay panel. If a candidate reduces C3b deposition, C5a generation, and sC5b-9 formation, the result may support upstream inhibition. If C3b deposition remains detectable while C5a, sC5b-9, or hemolysis is reduced, the candidate may act downstream, such as at C5 or terminal pathway assembly.

How long does a complement inhibition functional assay project take?

The timeline depends on assay complexity, number of candidates, number of pathways, sample availability, species, readouts, and whether custom optimization is required. For milestone-driven programs, Creative Biolabs can design staged workflows to support rapid early decisions followed by deeper confirmatory testing.

Can the assay be customized for my internal development criteria?

Yes. Creative Biolabs can customize pathway triggers, serum concentration, species matrix, target surface, detection antibodies, incubation conditions, inhibitor concentration range, controls, acceptance criteria, statistical outputs, and report format according to the client's internal decision framework.

What information should I provide before starting a project?

Useful information includes candidate format, target, expected mechanism of action, concentration, buffer composition, storage condition, species of interest, preferred pathway, sample type, available reference inhibitors, desired readouts, prior data, and the key decision the assay should support.